Corporate Presentation

Obesity Zealand Pharma has a rich obesity pipeline of differentiated product candidates Developed with GLP-1 receptor agonist foundation GLP-1 • Increase insulin sensitivity • • Delay gastric emptying Decrease appetite ZEAL& ZEALAND PHARMA Initially developed as monotherapy but with potential for combination + Glucagon • Increase energy expenditure • Reduce hepatic fat content • Stimulate lipolysis in fat tissue Survodutide dual GCG/GLP-1 receptor agonist + GLP-2 • Improve intestinal barrier function • Amylin Delay gastric emptying • Delay gastric emptying • ⚫ Restore leptin sensitivity . . Increase satiety Improve tolerability to GLP-1 Dapiglutide dual GLP-1/GLP-2 receptor agonist Petrelintide amylin analog GIP Stimulate insulin secretion Increase satiety Reduce nausea ZP 6590 GIP receptor agonist First-in-class potential, targeting obesity and the large sub-population with fatty liver co-morbidities, including NASH Novel MoA with first-in-class potential, targeting obesity and co-morbidities associated with low-grade inflammation, including NASH and neuro-inflammation, such as Alzheimer's disease Non-incretin MoA with best-in-class potential for obesity as monotherapy option with GLP-1RA-like weight loss but better tolerability and potential for preservation of muscle mass Targeting obesity with potential to complement GLP-1 for better effect and/or tolerability

View entire presentation